Indole-3-carbinol (I3C) and epigallocatechin-3-gallate (EGCG) combined with conventional therapy for ovarian cancer.
Ovarian cancer is the 7th most common cancer in females [1]. Depending on the stage at diagnosis, treatment typically involves surgery and platinum-based chemotherapy regimens, which have a range of side effects including but not limited to fatigue, nausea and vomiting, pain, insomnia, anemia, and peripheral neuropathy.
A 2018 study published in BMC Cancer looked at the effects of indole-3-carbinol and epigallocatechin-3-gallate (EGCG) in addition to chemotherapy and surgery on overall survival [2].
I3C is a natural compound found primarily in cruciferous vegetables (such as broccoli, kale, and Swiss chard), and EGCG is a natural compound found in green tea. This study demonstrated that I3C and EGCG as 5-year maintenance therapy given before, during and after platinum-based neoadjuvant and adjuvant chemotherapy and surgery significantly prolonged both progression-free and overall survival in patients with stage III and IV ovarian cancer, and also reduced incidence of ascites in recurrent ovarian cancer patients, compared to conventional therapy alone.
[1] https://www.wcrf.org/dietandcancer/ovarian-cancer
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148762/
Written by Dr. Dana Kolenich ND